Insider Transactions in Q1 2021 at Invitae Corp (NVTA)
Insider Transaction List (Q1 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 22
2021
|
Sean E George Director |
SELL
Open market or private sale
|
Direct |
3,675
-0.18%
|
$154,350
$42.72 P/Share
|
|
Mar 16
2021
|
Sean E George Director |
SELL
Bona fide gift
|
Direct |
5,750
-0.84%
|
-
|
|
Mar 15
2021
|
Shelly D Guyer Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
18,147
-3.75%
|
$762,174
$42.9 P/Share
|
|
Mar 15
2021
|
Sean E George Director |
SELL
Open market or private sale
|
Direct |
27,417
-1.95%
|
$1,151,514
$42.9 P/Share
|
|
Mar 15
2021
|
Katherine Stueland Chief Commercial Officer |
SELL
Grant, award, or other acquisition
|
Direct |
5,781
-2.68%
|
$242,802
$42.9 P/Share
|
|
Mar 15
2021
|
Katherine Stueland Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
12,443
-5.46%
|
$522,606
$42.9 P/Share
|
|
Mar 12
2021
|
Thomas Brida |
SELL
Open market or private sale
|
Direct |
16,051
-3.58%
|
$674,142
$42.9 P/Share
|
|
Mar 12
2021
|
Thomas Brida |
BUY
Grant, award, or other acquisition
|
Direct |
24,936
+9.87%
|
-
|
|
Mar 12
2021
|
Shelly D Guyer Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
24,936
+9.19%
|
-
|
|
Mar 12
2021
|
Robert L Nussbaum Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
18,159
-3.69%
|
$762,678
$42.9 P/Share
|
|
Mar 12
2021
|
Robert L Nussbaum Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
24,936
+9.06%
|
-
|
|
Mar 12
2021
|
Sean E George Director |
BUY
Grant, award, or other acquisition
|
Direct |
53,436
+7.0%
|
-
|
|
Mar 12
2021
|
Katherine Stueland Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
24,936
+9.86%
|
-
|
|
Mar 09
2021
|
Sean E George Director |
BUY
Exercise of conversion of derivative security
|
Direct |
23,333
+3.43%
|
$23,333
$1.26 P/Share
|
|
Mar 04
2021
|
Sean E George Director |
SELL
Open market or private sale
|
Direct |
3,675
-0.14%
|
$135,975
$37.63 P/Share
|
|
Mar 02
2021
|
Shelly D Guyer Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,000
-0.45%
|
$129,000
$43.34 P/Share
|
|
Mar 01
2021
|
Thomas Brida |
SELL
Open market or private sale
|
Direct |
5,000
-0.81%
|
$210,000
$42.94 P/Share
|
|
Feb 25
2021
|
Katherine Stueland Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
5,000
-0.61%
|
$200,000
$40.33 P/Share
|
|
Feb 25
2021
|
Katherine Stueland Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+2.35%
|
$50,000
$10.23 P/Share
|
|
Feb 22
2021
|
Geoffrey Crouse Director |
SELL
Open market or private sale
|
Direct |
10,000
-18.46%
|
$480,000
$48.87 P/Share
|
|
Feb 19
2021
|
Jason W. Myers Director |
SELL
Bona fide gift
|
Direct |
310,597
-75.65%
|
-
|
|
Jan 21
2021
|
Sean E George Director |
SELL
Open market or private sale
|
Direct |
8,675
-0.45%
|
$468,450
$54.52 P/Share
|
|
Jan 21
2021
|
Sean E George Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+0.77%
|
$40,000
$8.7 P/Share
|
|
Jan 13
2021
|
Katherine Stueland Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
4,199
-0.41%
|
$214,149
$51.17 P/Share
|
|
Jan 13
2021
|
Katherine Stueland Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,199
+1.99%
|
$41,990
$10.94 P/Share
|
|
Jan 06
2021
|
Robert L Nussbaum Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,101
+4.29%
|
$90,909
$9.9 P/Share
|